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Formulating the Research Question
Anuj Mehta, Brian Malley and Allan Walkey
Learning Objectives
• Understand how to turn a clinical question into a research question.
• Principles of choosing a sample.
• Approaches and potential pitfalls.
• Principles of deﬁning the exposure of interest.
• Principles of deﬁning the outcome.
• Selecting an appropriate study design.
9.1 Introduction
The clinical question arising at the time of most health-care decisions is: “will this
help my patient?” Before embarking on an investigation to provide data that may be
used to inform the clinical question, the question must be modiﬁed into a research
query. The process of developing a research question involves deﬁning several
components of the study and also what type of study is most suited to utilize these
components to yield valid and reliable results. These components include: in whom
is this research question relevant? The population of subjects deﬁned by the
researcher is referred to as the sample. The drug, maneuver, event or characteristic
that we are basing our alternative hypothesis on is called the exposure of interest.
Finally, the outcome of interest must be deﬁned. With these components in mind
the researcher must decide which study design is best or most feasible for
answering the question. If an observational study design is chosen, then the choice
of a database is also crucial.
In this chapter, we will explore how researchers might work through converting
a clinical question into a research question using the clinical scenario of indwelling
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arterial catheters (IAC) use during mechanical ventilation (MV). Furthermore, we
will discuss the strengths and weaknesses of common study designs including
randomized controlled trials as well as observational studies.
9.2 The Clinical Scenario: Impact of Indwelling Arterial
Catheters
Patients who require MV because they are unable to maintain adequate breathing on
their own (e.g. from severe pneumonia or asthma attack) are often the sickest
patients in the hospital, with mortality rates exceeding 30 % [1–3]. Multiple options
are available to monitor the adequacy of respiratory support for critically ill patients
requiring MV, ranging from non-invasive trans-cutaneous measures to invasive,
indwelling monitoring systems. IACs are invasive monitoring devices that allow
continuous real time blood pressure monitoring and facilitate access to arterial
blood sampling to assess arterial blood pH, oxygen and carbon dioxide levels,
among others [4–6]. While closer monitoring of patients requiring MV with IACs
may appear at face value to be beneﬁcial, IACs may result in severe adverse events,
including loss of blood flow to the hand and infection [7, 8]. Currently, data is
lacking whether beneﬁts may outweigh risks of more intensive monitoring using
IACs. Examining factors associated with the decision to use IACs, and outcomes in
patients provided IACs as compared to non-invasive monitors alone, may provide
information useful to clinicians facing the decision as to whether to place an IAC.
9.3 Turning Clinical Questions into Research Questions
The ﬁrst step in the process of transforming a clinical question into research is to
carefully deﬁne the study sample (or patient cohort), the exposure of interest, and
the outcome of interest. These 3 components—sample, exposure, and outcome—are
essential parts of every research question. Slight variations in each component can
dramatically affect the conclusions that can be drawn from any research study, and
whether the research will appropriately address the overarching clinical question.
9.3.1 Study Sample
In the case of IAC use, one might imagine many potential study samples of interest:
for example, one might include all ICU patients, all patients receiving MV, all
patients receiving intravenous medications that strongly affect blood pressure,
adults only, children only, etc. Alternatively, one could deﬁne samples based on
speciﬁc diseases or syndrome, such as shock (where IACs may be used to closely
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monitor blood pressure) or severe asthma (where IAC may be used to monitor
oxygen or carbon dioxide levels).
The choice of study sample will affect both the internal and the external validity
(generalizability) of the study. A study focusing only on a pediatric population may
not apply to the adult population. Similarly, a study focused on patients receiving
MV may not be applicable to non-ventilated patients. Furthermore, a study
including patients with different reasons for using an IAC, with different outcomes
related to the reason for IAC use, may lack internal validity due to bias called
‘confounding’. Confounding is a type of study bias in which an exposure variable is
associated with both the exposure and the outcome.
For instance, if the beneﬁts of IACs on mortality are studied in all patients
receiving MV, researchers must take into account the fact that IAC placement may
actually be indicative of greater severity of illness. For example, imagine a study
with a sample of MV patients in which those with septic shock received an IAC to
facilitate vasoactive medications and provide close blood pressuring monitoring
while patients with asthma did not receive an IAC as other methods were used to
monitor their ventilation (such as end-tidal CO2 monitoring). Patients with septic
shock tend to have a much higher severity of illness compared to patients with
asthma regardless of whether an IAC is placed. In such a study, researchers may
conclude that IACs are associated with higher mortality only because IACs were
used in sicker patients with a higher risk of dying. The variable “diagnosis” is
therefore a confounding factor, associated with both the exposure (decision to insert
an IAC) and the outcome (death). Careful sample selection is one method of
attempting to address issues of confounding related to severity of illness. Restricting
study samples to exclude groups that may strongly confound results (i.e. no patients
on vasoactive medications) is one strategy to reduce bias. However, the selection of
homogeneous study samples to increase internal validity should be balanced with the
desire to generalize study ﬁndings to broader patient populations. These principles
are discussed more extensively in the Chap. 10—“Cohort Selection”.
9.3.2 Exposure
The exposure in our research question appears to be fairly clear: placement of an
IAC. However, careful attention should be paid as to how each exposure or variable
of interest is deﬁned. Misclassifying exposures may bias results. How should IAC
be measured? For example, investigators may use methods ranging from direct
review of the medical chart to use of administrative claims data (i.e. International
Classiﬁcation of Diseases—ICD-codes) to identify IAC use. Each method of
ascertaining the exposure of interest may have pros (improved accuracy of medical
chart review) and cons (many person-hours to perform manual chart review).
Deﬁning the time window during which an exposure of interest is measured may
also have substantial implications that must be considered when interpreting the
research results. For the purposes of our IAC study, the presence of an IAC was
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deﬁned as having an IAC placed after the initiation of MV. The time-dependent
nature of the exposure is critical for answering the clinical question; some IACs
placed prior to MV are for monitoring of low-risk surgical patients in the operating
room. Including all patients with IACs regardless of timing may bias the results
towards a beneﬁt for IACs by including many otherwise healthy patients who had
an IAC placed for surgical monitoring. Alternatively, if the exposure group is
deﬁned as patients who had an IAC at least 48 h after initiation of MV, the study is
at risk for a type of confounding called “immortal time bias”: only patients who
were alive could have had an IAC placed, whereas patients dying prior to 48 h
(supposedly sicker) could not have had an IAC.
Equally important to deﬁning the group of patients who received or experienced
an exposure is to deﬁne the “unexposed” or control group. While not all research
requires a control group (e.g. epidemiologic studies), a control group is needed to
assess the effectiveness of healthcare interventions. In the case of the IAC study, the
control group is fairly straightforward: patients receiving MV who did not have an
IAC placed. However, there are important nuances when deﬁning control groups. In
our study example, an alternate control group could be all ICU patients who did not
receive an IAC. However, the inclusion of patients not receiving MV results in a
control group with a lower severity of illness and expected mortality than patients
receiving MV, which would bias in favor of not using IACs. Careful deﬁnition of
the control group is needed to properly interpret any conclusions from research;
deﬁning an appropriate control group is as important as deﬁning the exposure.
9.3.3 Outcome
Finally, the investigator needs to determine the outcome of interest. Several dif-
ferent types of outcomes can be considered, including intermediate or mechanistic
outcomes (informs etiological pathways, but may not immediately impact patients),
patient-centered outcomes (informs outcomes important to patients, but may lack
mechanistic insights: e.g. comfort scales, quality of life indices, or mortality), or
healthcare-system centered outcomes (e.g. resource utilization, or costs). In our
example of IAC use, several outcomes could be considered including intermediate
outcomes (e.g. number of arterial blood draws, ventilator setting changes, or
vasoactive medication changes), patient-centered outcomes (e.g. 28-day or 90-day
mortality, adverse event rates), or healthcare utilization (e.g. hospitalization costs,
added clinician workload). As shown in our example, outcome(s) may build upon
each other to yield a constellation of ﬁndings that provides a more complete picture
to address the clinical question of interest.
After clearly deﬁning the study sample, exposure of interest, and outcome of
interest, a research question can be formulated. A research question using our
example may be formulated as follows:
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“In the population of interest (study cohort), is the exposure to the variable of
interest associated with a different outcome than in the control group?”, which
becomes, in our example:
“Among mechanically ventilated, adult ICU patients who are not receiving
vasoactive medications (i.e., the study sample) is placement of an IAC after initi-
ation of MV (as compared with not receiving an IAC) (i.e. the exposure and control
patients) associated with improved 28-day mortality rates (primary outcome,
patient-centered) and the number of blood gas measurements per day (supporting
secondary outcome, intermediate/mechanistic)?”
9.4 Matching Study Design to the Research Question
Once the research question has been deﬁned, the next step is to choose the optimal
study design given the question and resources available. In biomedical research, the
gold-standard for study design remains the double-blinded, randomized,
placebo-controlled trial (RCT) [9, 10]. In a RCT, patients with a given condition
(e.g. all adults receiving MV) would be randomized to receive a drug or inter-
vention of interest (e.g. IAC) or randomized to receive the control (e.g. no IAC),
with careful measurement of pre-determined outcomes (e.g. 28-day mortality). In
ideal conditions, the randomization process eliminates all measured and unmea-
sured confounding and allows for causal inferences to be drawn, which cannot
generally be achieved without randomization. As shown above, confounding is a
threat to valid inferences from study results. Alternatively, in our example of septic
shock verses asthma, severity of illness associated with the underlying condition
may represent another confounder. Randomization solely based on the exposure of
interest attempts to suppress issues of confounding. In our examples, proper ran-
domization in a large sample would theoretically create equal age distributions and
equal numbers of patients with septic shock and asthma in both the exposure and
the control group.
However, RCTs have several limitations. Although the theoretical underpinnings
of RCTs are fairly simple, the complex logistics of patient enrollment and retention,
informed consent, randomization, follow up, and blinding may result in RCTs
deviating from the ‘ideal conditions’ necessary for unbiased, causal inference.
Additionally, RCTs carry the highest potential for patient harm and require inten-
sive monitoring because the study dictates what type of treatment a patient receives
(rather than the doctor) and may deviate from routine care. Given the logistic
complexity, RCTs are often time- and cost-intensive, frequently taking many years
and millions of dollars to complete. Even when logistically feasible, RCTs often
‘weed out’ multiple groups of patients in order to minimize potential harms and
maximize detection of associations between interventions and outcomes of interest.
As a result, RCTs can consist of homogeneous patients meeting narrow criteria,
which may reduce the external validity of the studies’ ﬁndings. Despite much effort
9.3 Turning Clinical Questions into Research Questions 85
and cost, an RCT may miss relevance to the clinical question as to whether the
intervention of interest is helpful for your particular patient or not. Finally, some
clinical questions may not ethically be answered with RCTs. For instance, the link
between smoking and lung cancer has never been shown in a RCT, as it is unethical
to randomize patients to start smoking in a smoking intervention group, or ran-
domize patients to a control group in a trial to investigate the efﬁcacy of parachutes
[11]!
Observational research differs from RCTs. Observational studies are
non-experimental; researchers record routine medical practice patterns and derive
conclusions based on correlations and associations without active interventions
[9, 12]. Observational studies can be retrospective (based on data that has already
been collected), prospective (data is actively collected over time), or
ambi-directional (a mix). Unlike RCTs, researchers in observational studies have no
role in deciding what types of treatments or interventions patients receive.
Observational studies tend to be logistically less complicated than RCTs as there is
no active intervention, no randomization, no data monitoring boards, and data is
often collected retrospectively. As such, observational studies carry less risk of harm
to patients (other than loss of conﬁdentiality of data that has been collected) than
RCTs, and tend to be less time- and cost-intensive. Retrospective databases like
MIMIC-II [13] or the National Inpatient Sample [14] can also provide much larger
study samples (tens of thousands in some instances) than could be enrolled in an
RCT, thus providing larger statistical power. Additionally, broader study samples
are often included in observational studies, leading to greater generalizability of the
results to a wider range of patients (external validity). Finally, certain clinical
questions that would be unethical to study in an RCT can be investigated with
observational studies. For example, the link between lung cancer and tobacco use
has been demonstrated with multiple large prospective epidemiological studies [15,
16] and the life-saving effects of parachutes have been demonstrated mostly through
the powers of observation.
Although logistically simpler than RCTs, the theoretical underpinnings of
observational studies are generally more complex than RCTs. Obtaining causal
estimates of the effect of a speciﬁc exposure on a speciﬁc outcome depends on the
philosophical concept of the ‘counterfactual’ [17]. The counterfactual is the situa-
tion in which, all being equal, the same research subject at the same time would
receive the exposure of interest and (the counterfactual) not receive the exposure of
interest, with the same outcome measured in the exposed and unexposed research
subject. Because we cannot create cloned research subjects in the real-world, we
rely on creating groups of patients similar to the group that receives an intervention
of interest. In the case of an ideal RCT with a large enough number of subjects, the
randomization process used to select the intervention and control groups creates
two alternate ‘universes’ of patients that will be similar except as related to the
exposure of interest. Because observational studies cannot intervene on study
subjects, observational studies create natural experiments in which the counter-
factual group is deﬁned by the investigator and by clinical processes occurring in
the real-world. Importantly, real-world clinical processes often occur for a reason,
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and these reasons can cause deviation from counterfactual ideals in which exposed
and unexposed study subjects differ in important ways. In short, observational
studies may be more prone to bias (problems with internal validity) than RCTs due
to difﬁculty obtaining the counterfactual control group.
Several types of biases have been identiﬁed in observational studies. Selection
bias occurs when the process of selecting exposed and unexposed patients introduces
a bias into the study. For example, the time between starting MV and receiving IAC
may introduce a type of “survivor treatment selection bias” since patients who
received IAC could not have died prior to receiving IACs. Information bias stems
from mismeasurement or misclassiﬁcation of certain variables. For retrospective
studies, the data has already been collected and sometimes it is difﬁcult to evaluate
for errors in the data. Another major bias in observational studies is confounding. As
stated, confounding occurs when a third variable is correlated with both the exposure
and outcome. If the third variable is not taken into consideration, a spurious rela-
tionship between the exposure and outcome may be inferred. For example, smoking
is an important confounder in several observational studies as it is associated with
several other behaviors such as coffee and alcohol consumption. A study investi-
gating the relationship between coffee consumption and incidence of lung cancer
may conclude that individuals who drink more coffee have higher rates of lung
cancer. However, as smoking is associated with both coffee consumption and lung
cancer, it is confounder in the relationship between coffee consumption and lung
cancer if unmeasured and unaccounted for in analysis. Several methods have been
developed to attempt to address confounding in observational research such as
adjusting for the confounder in regression equations if it is known and measured,
matching cohorts by known confounders, and using instrumental variables—
methods that will be explained in-depth in future chapters. Alternatively, one can
restrict the study sample (e.g. excluding patients with shock from a study evaluating
the utility of IACs). For these reasons, while powerful, an individual observational
study can, at best, demonstrate associations and correlations and cannot prove
causation. Over time, a cumulative sum of multiple high quality observational
studies coupled with other mechanistic evidence can lead to causal conclusions, such
as in the causal link currently accepted between smoking and lung cancer established
by observational human studies and experimental trials in animals.
9.5 Types of Observational Research
There are multiple different types of questions that can be answered with obser-
vational research (Table 9.1). Epidemiological studies are one major type of
observational research that focuses on the burden of disease in predeﬁned popu-
lations. These types of studies often attempt to deﬁne incidence, prevalence, and
risk factors for disease. Additionally, epidemiological studies also can investigate
changes to healthcare or diseases over time. Epidemiological studies are the
cornerstone of public health and can heavily influence policy decisions, resource
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allocation, and patient care. In the case of lung cancer, predeﬁned groups of patients
without lung cancer were monitored for years until some patients developed lung
cancer. Researchers then compared numerous risk factors, like smoking, between
those who did and did not develop lung cancer which led to the conclusion that
smoking increased the risk of lung cancer [15, 16].
There are other types of epidemiological studies that are based on similar
principles of observational research but differ in the types of questions posed.
Predictive modeling studies develop models that are able to accurately predict
future outcomes in speciﬁc groups of patients. In predictive studies, researchers
deﬁne an outcome of interest (e.g. hospital mortality) and use data collected on
patients such as labs, vital signs, and disease states to determine which factors
contributed to the outcome. Researchers then validate the models developed from
one group of patients in a separate group of patients. Predictive modeling studies
developed many common prediction scores used in clinical practice such as the
Framingham Cardiovascular Risk Score [18], APACHE IV [19], SAPS II [20], and
SOFA [21].
Comparative effectiveness research is another form of observational research
which involves the comparison of existing healthcare interventions in order to
determine effective methods to deliver healthcare. Unlike descriptive epidemiologic
studies, comparative effectiveness research compares outcomes between similar
patients who received different treatments in order to assess which intervention may
be associated with superior outcomes in real-world conditions. This could involve
comparing drug A to drug B or could involve comparing one intervention to a
control group who did not receive that intervention. Given that there are often
underlying reasons why one patient received treatment A versus B or an inter-
vention versus no intervention, comparative effectiveness studies must meticulously
account for potential confounding factors. In the case of IACs, the research question
comparing patients who had an IAC placed to those who did not have an IAC
placed would represent a comparative effectiveness study.
Pharmacovigilance studies are yet another form of observational research. As
many drug and device trials end after 1 or 2 years, observational methods are used
to evaluate if there are patterns of rarer adverse events occurring in the long-term.
Phase IV clinical studies are one form of pharmacovigilance studies in which
long-term information related to efﬁcacy and harm are gathered after the drug has
been approved.
Table 9.1 Major types of observational research, and their purpose
Type of observational research Purpose
Epidemiological Deﬁne incidence, prevalence, and risk factors for disease
Predictive modeling Predict future outcomes
Comparative effectiveness Identify intervention associated with superior outcomes
Pharmacovigilance Detect rare drug adverse events occurring in the long-term
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9.6 Choosing the Right Database
A critical part of the research process is deciding what types of data are needed to
answer the research question. Administrative/claims data, secondary use of clinical
trial data, prospective epidemiologic studies, and electronic health record
(EHR) systems (both from individual institutions and those pooled from multiple
institutions) are several sources from which databases can be built. Administrative or
claims databases, such as the National Inpatient Sample and State Inpatient
Databases complied by the Healthcare Cost and Utilization Project or the Medicare
database, contain information on patient and hospital demographics as well as billing
and procedure codes. Several techniques have been developed to translate these
billing and procedure codes to more clinically useful disease descriptions.
Administrative databases tend to provide very large sample sizes and, in some cases,
can be representative of an entire population. However, they lack granular
patient-level data from the hospitalization such as vital signs, laboratory and
microbiology data, timing data (such as duration of MV or days with an IAC) or
pharmacology data, which are often important in dealing with possible confounders.
Another common source of data for observational research is large epidemio-
logic studies like the Framingham Heart Study as well as large multicenter RCTs
such as the NIH ARDS Network. Data that has already been can be analyzed
retrospectively with new research questions in mind. As the original data was
collected for research purposes, these types of databases often have detailed,
granular information not available in other clinical databases. However, researchers
are often bound by the scope of data collection from the original research study
which limits the questions that may be posed. Importantly, generalizability may be
limited in data from trials.
The advent of Electronic Health Records (EHR) has resulted in the digitization of
medical records from their prior paper format. The resulting digitized medical
records present opportunities to overcome some of the shortcomings of adminis-
trative data, yielding granular data with laboratory results, medications, and timing
of clinical events [13]. These “big databases” take advantage of the fact many EHRs
collect data from a variety of sources such as patient monitors, laboratory systems,
and pharmacy systems and coalesce them into one system for clinicians. This
information can then be translated into de-identiﬁed databases for research purposes
that contain detailed patient demographics, billing and procedure information,
timing data, hospital outcomes data, as well as patient-level granular data and pro-
vider notes which can searched using natural language processing tools. “Big data”
approaches may attenuate confounding by providing detailed information needed to
assess severity of illness (such as lab results and vital signs). Furthermore, the
granular nature of the data can provide insight as to the reason why one patient
received an intervention and another did not which can partly address confounding
by indication. Thus, the promise of “big data” is that it contains small, very detailed
data. “Big data” databases, such as MIMIC-III, have the potential to expand the
scope of what had previously been possible with observational research.
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9.7 Putting It Together
Fewer than 10 % of clinical decisions are supported by high level evidence [22].
Clinical questions arise approximately in every other patient [23] and provide a
large cache of research questions. When formulating a research question, investi-
gators must carefully select the appropriate sample of subjects, exposure variable,
outcome variable, and confounding variables. Once the research question is clear,
study design becomes the next pivotal step. While RCTs are the gold standard for
establishing causal inference under ideal conditions, they are not always practical,
cost-effective, ethical or even possible for some types of questions. Observational
research presents an alternative to performing RCTs, but is often limited in causal
inference by unmeasured confounding.
Our clinical scenario gave rise to the question of whether IACs improved the
outcomes of patients receiving MV. This translated into the research question:
“Among mechanically ventilated ICU patients not receiving vasoactive medications
(study sample) is use of an IAC after initiation of MV (exposure) associated with
improved 28-day mortality (outcome)?” While an RCT could answer this question,
it would be logistically complex, costly, and difﬁcult. Using comparative effec-
tiveness techniques, one can pose the question using a granular retrospective
database comparing patients who received an IAC to measurably similar patients
who did not have an IAC placed. However, careful attention must be paid to
unmeasured confounding by indication as to why some patients received IAC and
others did not. Factors such as severity of illness, etiology of respiratory failure, and
presence of certain diseases that make IAC placement difﬁcult (such as peripheral
arterial disease) may be considered as possible confounders of the association
between IAC and mortality. While an administrative database could be used, it
could lack important information related to possible confounders. As such, EHR
databases like MIMIC-III, with detailed granular patient-level data, may allow for
measurement of a greater number of previously unmeasured confounding variables
and allow for greater attenuation of bias in observational research.
Take Home Messages
• Most research questions arise from clinical scenarios in which the proper course
of treatment is unclear or unknown.
• Deﬁning a research question requires careful consideration of the optimal study
sample, exposure, and outcome in order to answer a clinical question of interest.
• While observational research studies can overcome many of the limitations of
randomized controlled trials, careful consideration of study design and database
selection is needed to address bias and confounding.
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